DalCor Pharmaceuticals

DalCor Pharmaceuticals is focused on developing precision treatments for cardiovascular disease by leveraging genetic targeting to improve patient outcomes. The company’s lead program, dalcetrapib, aims to reduce cardiovascular events in patients with a specific genetic profile. In a significant pharmacogenomics analysis conducted on a subset of participants from a large clinical study, it was found that patients with acute coronary syndrome possessing a particular genetic polymorphism in the ADCY9 gene experienced fewer cardiovascular events when treated with dalcetrapib, a CETP inhibitor, compared to a placebo. DalCor holds an exclusive worldwide license for dalcetrapib from Roche, along with the rights to the associated ADCY9 genetic marker. By combining clinical, biological, and genetic insights, DalCor seeks to effectively address the residual cardiovascular risk in genetically distinct patient populations, ultimately enhancing therapeutic efficacy.